COO Cooper Companies, Inc.

$COO insider buying continues: Director Lawrence Kurzius bought 10,000 shares on Sept. 14 at $53.92—and another 10,000 on Sept. 16 at $54.93. Total: 20,000 shares worth about $1.09M in five days. Strong vote of confidence

$COO @ 53.27 - and down from SP +75 in 3 months, even with downgrades- it is now undervalued and very low risk for entry- imo

$COO A few insider buys, mind you their buys from last year are 30 to 40% underwater so......

$COO Bearish — a revenue miss plus a slashed full-year guide is the one combo that gets zero sympathy from the algos. Cooper handed value hunters a "46% undervalued" banner while the tape pinned it to a fresh 52-week low, which is exactly how a falling knife recruits volunteers.🤑

• Structure: The Cooper Companies, Inc. ($COO) on the weekly chart is working to rebuild a base around $56.50–$57.50 - Reclaiming resistance at $60.00–$63.00 clears the way to fill the gap toward higher targets at $70.00 and $75.00+. Losing support at $53.00–$54.00 risks a retest of the $51.01 52-week lows. • Business: The Cooper Companies, Inc. is a leading global medical device provider operating through CooperVision (contact lenses) and CooperSurgical (women's health, fertility, and surgical products). 🎯 Key Levels: 🐂 Bull Trigger: $60.00 / $63.00 🚀 Targets: $70.00 / $75.00 / $82.00 🛡 Support: $56.50 / $53.00 ⚠ Risk: $51.00 / $45.00 🔥 Volume & Flow: • 📊 Institutional dark pool accumulation stacking massive size: $20.6M block print (358.5K shares) at $57.41, $7.1M block print (125.9K shares) at $56.63, $5.6M block print (98.9K shares) at $56.48, and $5.5M block print (97.5K shares) at $56.45. Over $38.8M in total dark pool premium crossing the tape. #hovdid

$COO | Snapshot 📊⚡• Business: The Cooper Companies, Inc., a global medical device company specializing in contact lenses (CooperVision) and women's health/fertility solutions (CooperSurgical).• Financial Health & Pipeline: Strong quarterly free cash flow ($273M) and $1B share buyback authorization balancing lower near-term CooperVision inventory headwinds.• Bias & Conviction: Neutral-to-Bullish Demand Test | Moderate Conviction (Descending channel selling into high-volume profile support shelf at $51.00–$54.00). 🎯 Key Levels: 🐂 Bull Trigger: $58.00 / $65.00 🚀 Targets: $65.00 / $71.00 / $80.00+ 🛡️ Support: $54.00 / $51.00 ⚠️ Risk: $51.00 / $45.00 🔥 Options Flow: • 🟢 Institutional consolidation along weekly volume support; monitoring incoming block & sweep flow above $58.00 trigger. #COO #medtech #healthcare #stocks #hovdid

$COO CooperCompanies (COO) opened CooperVision’s global innovation hub, The Vision Centre, and outlined six contact lens advancements on September 23, 2026. The Southampton, England, facility brings together research and development, clinical expertise, pilot manufacturing and commercial capabilities.

I looked at the business behind $COO (COOPER COMPANIES, INC.) for you. Based on financial data and reported results. #COO

$COO | Comprehensive Trade Setup 📊💥 • Business & Fundamentals: Global medical device leader specializing in contact lenses (CooperVision) and women’s health surgical products and fertility solutions (CooperSurgical). • Market Structure: 8H timeframe breaking above its steep short-term falling trendline following a deep flush to the $51.00 base. Rebounding back toward the lower boundary of a massive volume profile node. Key Technical Breakdown: • Key Confirmation Pivot: $58.00 • Core Support Base: $53.74 • Overhead Target Objectives: $68.00 / $78.00 / $88.00 • Risk Invalidation Floor: $47.00 Options Flow Implied Targets: • Active Flow: 10/16 $55 Calls ($73.8K opening sweep) • Flow Type: Bullish positioning anticipating a momentum push through near-term resistance Tactical Outlook: A decisive 8H push above $58.00 confirms the macro oversold bottom, driving price toward major high-volume resistance nodes at $68.00 and $78.00 as long as $53.74 holds as primary support. #COO #hovdid

$COO Good business, but terrible decision-making, poor execution and implementation from top to bottom.

$COO -14% to $54.51 after a Q3 revenue miss and weak guidance, plus investors annoyed the board is keeping CooperSurgical instead of the spinoff they wanted. Screener's torn on it: RSI 14.8, deep oversold, Reversal Watch flipped Buy 2 days ago - but Yearly Extremes just flipped Sell an hour ago on a fresh 52-week low, with a Death Cross running underneath since April. Capitulation bounce or further downside from here?